22
Participants
Start Date
December 7, 2021
Primary Completion Date
May 23, 2024
Study Completion Date
December 31, 2029
rilzabrutinib
Pharmaceutical form: Tablet Route of administration: Oral
Hanush-Krankenhaus_Investigational Site Number: 0400001, Vienna
Odense Universitetshospital Hæmatologisk Forskningsenhed_Investigational Site Number: 2080001, Odense
Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz_Investigational Site Number: 3480001, Székesfehérvár
Georgetown University Hospital_Investigational Site Number: 8400003, Washington D.C.
Ospedale Maggiore Policlinico_Investigational Site Number: 3800001, Milan
Hospital Universitario La Paz_Investigational Site Number: 7240003, Madrid
Oncology & Hematology Associates of West Broward_Investigational Site Number: 8400002, Tamarac
Hospital Universitario Virgen del Rocío_Investigational Site Number: 7240002, Seville
Klinik für Hämatologie und Stammzellentransplantation_Investigational Site Number: 2760001, Essen
"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori_Investigational Site Number: 3800003", Meldola
Hospital Universitario de Cruces_Investigational Site Number: 7240004, Barakaldo
Ospedale Giuseppe Moscati_Investigational Site Number: 3800002, Avellino
University of Southern California_Investigational Site Number: 8400009, Los Angeles
The Lundquist Institute_Investigational Site Number: 8400005, Torrance
TOI Clinical Research LLC_ Whittier_Investigational Site Number: 8400006, Whittier
The Oncology Institute of Hope & Innovation Site Number : 8400006, Cerritos
TOI Clinical Research LLC_ Cerritos_Investigational Site Number: 8400006, Cerritos
TOI Clinical Research LLC_Long Beach_Investigational Site Number: 8400006, Long Beach
TOI Clinical Research LLC_Glendale_Investigational Site Number: 8400006, Glendale
TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006, Santa Ana
Peking Union Medical College Hospital_Investigational Site Number: 1560002, Beijing
Institute of hematology&blood diseases hospital_Investigational Site Number: 1560003, Tianjin
Massachusetts General Hospital_Investigational Site Number: 8400001, Boston
Hospital Clinic de Barcelona_Investigational Site Number: 7240001, Barcelona
Leeds Teaching Hospitals NHS Trust_Investigational Site Number: 8260001, Leeds
Barts Health NHS Trust_Investigational Site Number: 8260005, London
Imperial College Healthcare NHS Trust_Investigational Site Number: 8260002, London
Lead Sponsor
Sanofi
INDUSTRY